

Romania

Tuberculosis profile

Population 2016

20 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	1 (1–1)	5.1 (5–5.1)
Mortality (HIV+TB only)	0.059 (0.043–0.079)	0.3 (0.22–0.4)
Incidence (includes HIV+TB)	15 (13–17)	74 (64–86)
Incidence (HIV+TB only)	0.37 (0.31–0.43)	1.9 (1.6–2.2)
Incidence (MDR/RR-TB)**	0.89 (0.75–1)	4.5 (3.8–5.2)

Estimated TB incidence by age and sex (thousands)*, 2016			
	0-14 years	> 14 years	Total
Females	0.77 (0.65–0.89)	4 (3.4–4.6)	4.8 (4.1–5.5)
Males	0.87 (0.74–1)	9.1 (7.7–10)	9.9 (8.4–11)
Total	1.6 (1.4–1.9)	13 (11–15)	15 (13–17)

TB case notifications, 2016	
Total cases notified	13 617
Total new and relapse	12 790
- % tested with rapid diagnostics at time of diagnosis	5%
- % with known HIV status	73%
- % pulmonary	84%
- % bacteriologically confirmed among pulmonary	82%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2016	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.07 (0.06–0.08)

TB/HIV care in new and relapse TB patients, 2016		Number	(%)
Patients with known HIV-status who are HIV-positive		254	3%
- on antiretroviral therapy		254	100%

Drug-resistant TB care, 2016			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			730 (670–790)
Estimated % of TB cases with MDR/RR-TB	2.8% (2.4–3.3)	17% (16–19)	
% notified tested for rifampicin resistance	56%	73%	8 170
MDR/RR-TB cases tested for resistance to second-line drugs			251
Laboratory-confirmed cases		MDR/RR-TB: 536, XDR-TB: 63	
Patients started on treatment ****		MDR/RR-TB: 590, XDR-TB: 63	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2015	85%	13 908
Previously treated cases, excluding relapse, registered in 2015	47%	682
HIV-positive TB cases registered in 2015	63%	261
MDR/RR-TB cases started on second-line treatment in 2014	44%	539
XDR-TB cases started on second-line treatment in 2014	16%	57

TB preventive treatment, 2016	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2017	
National TB budget (US\$ millions)	17
Funding source: 40% domestic, 29% international, 30% unfunded	


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016




Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically